Pe-042-3 Alteration ampygglial activation to pain-evoked processing in patients with fibromyalgia
Pe-00506 D-31-34 Novel secondary prevention trials: by integrativeigital-specific treatment adherence of ACE
Pe-01151 D-00-04 Intracranial TUBULAR ACCESS in INFRATENTORIAL COMPTETENT ADULT: UNUSUAL FINDING
Pe-01211 D-01-05 EFFECT of NADOLOL INJECTED PRIOR TO CORTI ON STRESS-INDUCED PAPILLARY CONGESTION LEVEL 2.66
Pe-01132 D-10-04 The Pedicled Rectus Abdominis: A Resource for Reconstructing Spinal Muscle Atrophy
Pe-01161 D-10-06 VNO5-531 Gene Replacement Therapy for Spinal Musculo Atrophy Type 1 (SMA): Pilot Study: STAGE 1, Update
Pe-01244 withdrew Pe-0111 Evaluation of diagnostic markers between Cancer-related stroke and Atoll fractionation.
Pe-01536 D-00-01 Neuromuscular pain syndromes affecting patients with hyperphosphatemic vascular dysplasia
Pe-01584 withdrew Pe-0104 Effect & Tolerability of Bimatoprost in the Treatment of Stabile Hyperopia: A Systematic Review
Pe-01614 D-01-05 Motor potentials evoked by navigated transcranial magnetic stimulation in healthy subjects
Pe-01625 D-10-04 VNO5-531 Gene Replacement Therapy in Preclinical Spinal Muscular Atrophy (SMA): Study Update
Pe-01663 withdrew Pe-074-6 Use of linear analysis MRI during the noninvasive path of transgenic model
Pe-01698 D-00-05 Altered Fetal Tissue Network Relationships to Memory Skills in Glied AD Patients
Pe-01701 withdrew Pe-073-2 Medication of KAE by oral administration of Meclofenac sodium vs placebo in cortisol secretion
Pe-01750 D-10-16 Clinical features of patients with anti-LGI1 associated encephalitis: a Chinese case series
Pe-01773 D-36-1 Neurodevelopmental effects of prolonged midweek sleep deprivation in Rats/C mice
Pe-01781 disclosed Pe-013-2 Cognitive dysfunction in Nulceus System Atrophy-C
Pe-02083 disclosed Pe-03-01 Manifesta Basilar Artery Athero in Alzheimer’s disease with history of Vital Drug Exposure
Pe-02089 disclosed Pe-01-02 Lumbosacral vertebral and basal ganglia changes in CADASIL, a 7.0-7 MRI study.
Pe-02099 disclosed Pe-00-04 Evaluation of DEPRESSION IN PEOPLE WITH CHINESE HEADACHE in HONGKONG
Pe-02093 disclosed Pe-01-04 Evaluation of MIGRAINE HEADACHE in PERUVIAN
Pe-02092 disclosed Pe-00-04 Magnetic Resonance Imaging (MRI) Findings in non-convulsive epileptic state (NCSE).
Pe-02091 disclosed Pe-00-04 Regulation of stomach in acidophilic and fibrotic histopathology in hyperplastic acidophilic hyperplasia.
Pe-02090 disclosed Pe-00-04 Anti-Ro antibodies frequently co-occur with other myositis autoantibodies
Pe-02087 disclosed Pe-00-04 Anti-Ro antibodies frequently co-occur with other myositis autoantibodies
Pe-02086 disclosed Pe-00-04 Anti-Ro antibodies frequently co-occur with other myositis autoantibodies
Pe-02081 disclosed Pe-00-04 Anti-Ro antibodies frequently co-occur with other myositis autoantibodies
Pe-02079 disclosed Pe-00-04 Anti-Ro antibodies frequently co-occur with other myositis autoantibodies
Pe-02097 disclosed Pe-00-04 Anti-Ro antibodies frequently co-occur with other myositis autoantibodies
Pe-02085 disclosed Pe-00-04 Anti-Ro antibodies frequently co-occur with other myositis autoantibodies
Pe-02084 disclosed Pe-00-04 Anti-Ro antibodies frequently co-occur with other myositis autoantibodies
Pe-02082 disclosed Pe-00-04 Anti-Ro antibodies frequently co-occur with other myositis autoantibodies
Pe-01119 withdrew Pe-01-01 Kickin' of human K-5 channel breakdown and gap at SCP/Hc-associated mutations
Pe-01132 withdrawn Pe-0114 Regulation of surface GLC-1 chloride channel stability by PPAR
Pe-01162 Pe-005-4 The relationship between orthodontic hypotension and motor performance in batho patients.
Pe-01166 Pe-002-5 CLINICAL EVALUATION OF SLEEP DISORDERS IN PATIENTS WITH PARKINSON'S DISEASE
Pe-01173 Pe-007-3 A mutation of flavim-c causing myofibrillary myopathy with lower motor neuron syndrome
Pe-01177 Pe-009-5 A case of 5-6 year old male with Neurofibromatosis Syndrome Pre-estimate as Status Quo
Pe-01175 Pe-004-4 Evaluation of migrainous headache following Malaria P. falciparum- a rare neurological sequela.
Pe-01176 Pe-004-4 Evaluation of migrainous headache following Malaria P. falciparum- a rare neurological sequela.
Pe-01198 Pe-001-6 The Neuroprotective Effect of Proteasomes Inhibition in Intracerebral Hemorrhage Rats
Pe-01199 Pe-004-4 The Value of VEP(Visual Evoked Potential) in Diagnosing MS(Multiple Sclerosis)
Pe-01200 Pe-003-4 Neuroprotective impact of N-butanol fraction of Myristica fragrans in Alzheimer disease.
Pe-01198 Pe-004-4 The Value of VEP(Visual Evoked Potential) in Diagnosing MS(Multiple Sclerosis)
Pe-01199 Pe-004-4 The Value of VEP(Visual Evoked Potential) in Diagnosing MS(Multiple Sclerosis)
Pe-01200 Pe-003-4 Neuroprotective impact of N-butanol fraction of Myristica fragrans in Alzheimer disease.
Pe-01201 Pe-003-4 Neuroprotective impact of N-butanol fraction of Myristica fragrans in Alzheimer disease.
Pe-01202 Pe-003-4 Neuroprotective impact of N-butanol fraction of Myristica fragrans in Alzheimer disease.
Pe-01198 Pe-004-4 The Value of VEP(Visual Evoked Potential) in Diagnosing MS(Multiple Sclerosis)
Pe-01199 Pe-004-4 The Value of VEP(Visual Evoked Potential) in Diagnosing MS(Multiple Sclerosis)
Pe-01200 Pe-003-4 Neuroprotective impact of N-butanol fraction of Myristica fragrans in Alzheimer disease.
Pe-01201 Pe-003-4 Neuroprotective impact of N-butanol fraction of Myristica fragrans in Alzheimer disease.
Pe-01202 Pe-003-4 Neuroprotective impact of N-butanol fraction of Myristica fragrans in Alzheimer disease.
Pe-01198 Pe-004-4 The Value of VEP(Visual Evoked Potential) in Diagnosing MS(Multiple Sclerosis)
Pe-01199 Pe-004-4 The Value of VEP(Visual Evoked Potential) in Diagnosing MS(Multiple Sclerosis)
Pe-01200 Pe-003-4 Neuroprotective impact of N-butanol fraction of Myristica fragrans in Alzheimer disease.
Pe-01201 Pe-003-4 Neuroprotective impact of N-butanol fraction of Myristica fragrans in Alzheimer disease.
Pe-01202 Pe-003-4 Neuroprotective impact of N-butanol fraction of Myristica fragrans in Alzheimer disease.
<table>
<thead>
<tr>
<th>Submitted Abstract ID</th>
<th>Presentation Date</th>
<th>Start</th>
<th>End</th>
<th>Room</th>
<th>Presentation/Style</th>
<th>Session Title</th>
<th>Season Title</th>
<th>Order</th>
<th>Travel Grant Winner</th>
</tr>
</thead>
<tbody>
<tr>
<td>1001315 Pe-061-3</td>
<td>5/24(Fri)</td>
<td>16:00</td>
<td>17:15</td>
<td></td>
<td>Poster Sleep</td>
<td></td>
<td></td>
<td>3</td>
<td>TG</td>
</tr>
<tr>
<td>1001339 Pe-002-3</td>
<td>5/22(Wed)</td>
<td>17:20</td>
<td>18:35</td>
<td></td>
<td>Poster Sleep</td>
<td></td>
<td></td>
<td>3</td>
<td>TG</td>
</tr>
<tr>
<td>1001341 Pe-063-5</td>
<td>5/25(Sat)</td>
<td>13:15</td>
<td>14:30</td>
<td></td>
<td>Poster Sleep</td>
<td></td>
<td></td>
<td>5</td>
<td>TG</td>
</tr>
<tr>
<td>1001343 Pe-059-2</td>
<td>5/24(Fri)</td>
<td>16:00</td>
<td>17:15</td>
<td></td>
<td>Poster Peripheral neuropathy (Peripheral neuropathy (GBS・PGS))</td>
<td>2</td>
<td>TG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1001344 Pe-063-5</td>
<td>5/25(Sat)</td>
<td>13:15</td>
<td>14:30</td>
<td></td>
<td>Poster Peripheral neuropathy (Peripheral neuropathy (GBS・PGS))</td>
<td>2</td>
<td>TG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1001349 Pe-063-5</td>
<td>5/25(Sat)</td>
<td>13:15</td>
<td>14:30</td>
<td></td>
<td>Poster Peripheral neuropathy (Peripheral neuropathy (GBS・PGS))</td>
<td>2</td>
<td>TG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1001356 O-36-4</td>
<td>5/24(Fri)</td>
<td>09:45</td>
<td>11:15</td>
<td>Room 13</td>
<td>Oral neuropathology</td>
<td></td>
<td></td>
<td>4</td>
<td>TG</td>
</tr>
<tr>
<td>1001357 Pe-061-4</td>
<td>5/24(Fri)</td>
<td>16:00</td>
<td>17:15</td>
<td></td>
<td>Poster Sleep</td>
<td></td>
<td></td>
<td>4</td>
<td>TG</td>
</tr>
<tr>
<td>1001358 Pe-002-4</td>
<td>5/22(Wed)</td>
<td>17:20</td>
<td>18:35</td>
<td></td>
<td>Poster Sleep</td>
<td></td>
<td></td>
<td>4</td>
<td>TG</td>
</tr>
</tbody>
</table>

If you are nominated as a presenter at the "Nominees for Best Presentation Award for the International Participants," please prepare for the poster presentation in addition to your general oral/poster presentation.